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Abstract
Clinical studies have confirmed that renal oncocytoma (RO) is a benign neoplasm with excellent prognosis. In 
diagnostically challenging cases of renal oncocytic epithelial neoplasms, fluorescent in-situ hybridization (FISH) is 
increasingly being used and its ability to distinguish RO from chromophobe renal cell carcinoma (ChRCC) has been 
documented. In this study, we evaluated the differential diagnostic contribution of FISH in cases of RO.
Clinicopathologic data and glass slides from 73 patients with RO were reviewed; 20 cases of ChRCC were included for 
comparison. FISH analysis of formalin-fixed, paraffin-embedded sections was performed using centromeric probes for 
chromosomes 1, 2, 7 and 17. FISH analysis revealed ROs had frequent loss of signal for chromosome 1 (56%) and 17 
(44%). Tumors with more than one loss were common (41%) and 10% cases showed loss of all chromosomes 
examined. A total of 18% cases did not show any abnormality.
Our study shows that chromosomal abnormalities in both ROs and ChRCCs are common with frequent loss of 
chromosomes 1 and 17. No association was found between overall patient survival and the extent of chromosomal 
abnormalities. FISH results, even those showing significant chromosomal abnormalities, should not alter the primarily 
morphology-based diagnosis of RO.
Introduction
Renal oncocytomas (ROs) comprise approximately 3-7%
of renal epithelial neoplasms [1-3]. Common origin of RO
and chromophobe renal cell carcinoma (ChRCC) from
the intercalated cells of collecting ducts explains the his-
tomorphologic, immunophenotypical, ultrastructural
and molecular similarities of both neoplasms [2-7]. The
benign nature of ROs, compared with the potential of
ChRCCs for metastases and sarcomatoid transformation
[8,9] has led to search for a confirmatory diagnostic
modality; a broad array of ancillary studies have been
employed in the differential diagnosis of the two neo-
plasms, including electron microscopy, flow cytometry,
immunohistochemistry, cytogenetics and fluorescent in
situ hybridization (FISH).
Cytogenetic studies of RO revealed genetic heterogene-
ity of these neoplasms; three distinct subsets were identi-
fied: 1) translocation between 11q13 and other
chromosomes, 2) loss of 1/1p followed by loss of chromo-
some Y or 14 and 3) non-recurrent or no detectable aber-
rations [10]. Molecular and fluorescent in-situ
hybridization (FISH) studies of ROs described partial or
total loss of chromosome 1 to be the most consistently
reported clonal chromosomal abnormality in RO [11-13]
with a possible tumor suppressor gene expected on chro-
mosome 1p [14]. In contrast, ChRCC was consistently
found to display multiple losses of chromosomes 1, 2, 6,
10, 17 and 21 [12,15-17]. FISH was considered to be a
potentially useful tool for distinguishing RO from
ChRCC, with the former showing no abnormality or loss
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of chromosome 1 and the latter usually multiple addi-
tional chromosomal aberrations [12,18].
Based on the current data on genetic abnormalities
occurring in ROs, we have employed an abbreviated FISH
panel for chromosomes 1, 2, 7 and 17 in our institution
that would aid in their differential diagnosis. In this study,
we present our experience with this FISH panel and its
contribution in the differential diagnosis along with sur-
vival data of 73 patients with RO.
Materials and methods
Case selection
The pathology records of the University of Pittsburgh
were reviewed to find all patients who underwent pri-
mary nephrectomy for renal oncocytoma in the period of
25 years (1981 - 2006). Seventy-three cases of renal onco-
c y t o m a  w e r e  s e l e c t e d  f r o m  t h e  U P M C  a r c h i v e s  u s i n g
conventional histologic examination by two pathologists.
For each patient, the data from the final surgical pathol-
ogy report as well as from the clinical records were
retrieved. In addition, 20 cases of ChRCC (11 cases of
classic and 9 cases of eosinophilic variant) were included
for comparison. Since the previously published FISH
results did not show significant difference in observed
abnormalities between the classic and eosinophilic vari-
ant of ChRCC [12], the two subtypes were not distin-
guished further in our study. Five (5) non-neoplastic
kidney tissue sections were evaluated as a negative con-
trol.
Fluorescent in-situ hybridization
Formalin-fixed paraffin-embedded sections were
mounted and serially sectioned at 5-mm intervals. H&E
section was used by the pathologist to determine the area
of the tissue to be targeted for analysis. FISH slides were
deparaffinized in xylene twice for 10 minutes, dehydrated
twice with 100% ethanol and then pretreated using the
Vysis Paraffin Pretreatment Kit. Slides were digested for
18 minutes in protease solution (0.5 mg/ml) at 37°C.
FISH was performed using CEP1, CEP2, CEP7 and
CEP17 centromere probes (Vysis, Inc., Downers Grove,
IL). The target slide was denatured at 75°C for 5 minutes
and dehydrated in 70%, 85%, 100% ethanol. Slides were
incubated with probe overnight at 42°C in a humidified
chamber. Post-hybridization washes were performed
using 0.4× SSC/0.3% Igepal (Sigma) at 72°C for 2 minutes,
followed by a room temperature 2 × SSC/0.1% Igepal
wash for 30 seconds. Slides were air-dried in the dark and
counterstained with DAPI (Vysis, Inc). Analysis was per-
formed using a Nikon Optiphot-2 (Nikon, Inc) and Quips
Genetic Workstation equipped with Chroma Technology
83000 filter set with single band excitors for Texas Red/
Rhodamine, FITC, DAPI (UV 360 nm) (Vysis, Inc). Only
individual and well delineated cells were scored, overlap-
ping cells were excluded from the analysis. At least 60
cells were analyzed in the targeted region. Signal loss was
considered significant if present in more than 30% of
cells, gain if present in more than 20% of cells examined.
Results
Clinico-pathological characteristics of the study population 
with clinical follow-up
In the RO group, the study population included 51 males
and 22 females (male to female ratio 2.3:1) with an aver-
age age of 67 (range 29 - 83) years. A total of 32 patients
44%) underwent partial nephrectomy (nephron sparing
surgery), the remaining 41 patients (56%) radical nephre-
ctomy with or without ipsilateral adrenalectomy. The
mean tumor size was 4.0 cm (range from 1 - 21 cm).
Small vessel invasion was present in 4 (5.5%) cases, and
invasion into perinephric adipose tissue in 5 (6.8%) cases.
None of the patients had evidence of metastatic disease at
diagnosis. After a mean follow-up of 64 months (range
from 1 to 293 months), a total of 46 (63%) of patients were
alive with no evidence of disease; 14 (19%) had died of
other causes and no follow up was available for 13 (18%)
patients. None of the patients had disease recurrence nor
developed metastases. The control ChRCC group con-
sisted of 11 males and 9 females male to female ratio
1.2:1) with a mean age of 64 (range 35 - 88) years (Table
1). Average tumor size was 6.1 cm (range 1 - 14.5 cm). A
total of 8 patients (40%) were treated with partial nephre-
ctomy, 12 (60%) with radical nephrectomy. Small vessel
invasion was present in 3 (15%) cases, and invasion into
perinephric adipose tissue in 2 (10%) cases; one patient
had tumor grossly extending into the renal vein. After a
mean follow up of 60 months (range from 25 - 87
months), one patient with a tumor extending into the
perinephric adipose tissue developed local recurrence 25
months after a radical nephrectomy. Similarly to the renal
oncocytoma group, none of the patients with available
follow-up died of disease or developed metastases.
Characteristic histological features of both RO and
ChRCC were observed (Figures 1 and 2). ROs exhibited a
mix of architectural patterns; most commonly the "clas-
sic" organoid pattern with nests of polygonal to round
oncocytes with abundant densely granular eosinophilic
cytoplasm and round nuclei embedded in loose myxoid
or hyalinized stroma. Other patterns were also seen (Fig-
ure 1). ChRCCs showed compact architecture of solid
sheets, nests, acini or broad trabeculae composed of large
polygonal cells with distinct cell borders, abundant retic-
u l a r  c y t o p l a s m ,  i r r e g u l a r  n u c l e i  w i t h  w r i n k l e d  n u c l e a r
membrane and frequent binucleation (Figure 2).
In 32 cases, the initial diagnosis of renal oncocytoma
was based on histology alone (44%); a total of 41 (56%)
cases had some ancillary studies, such as electron micros-
copy (2 cases, 3%), DNA ploidy analysis (3 cases, 4%),Dvorakova et al. Diagnostic Pathology 2010, 5:32
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FISH (24 cases, 33%) or histochemistry for Hale's colloi-
dal iron (12 cases, 16%). A total of 68 cases (93%) were
initially diagnosed as oncocytoma; however, 5 cases (7%)
were diagnosed using descriptive terms such as "atypical
oncocytic neoplasm" or "renal cell carcinoma of onco-
cytic type (oncocytoma)". In contrast, all of the chromo-
phobe renal cell carcinomas were initially worked-up
using ancillary studies such as Hale's colloidal iron his-
tochemical stain (19/20 cases, 95%) or FISH (12/20 cases,
60%).
FISH analysis
The FISH results are summarized in Table 2 and Figure 3.
Tumors with more than one loss were common (30/73,
41%) and 7/73 (10%) cases showed loss of one signal in all
chromosomes examined. A total of 13 (18%) cases did not
show significant losses or gains when compared to nor-
mal renal tissue. Loss of chromosome 1 (41/73, 56%) and
17 (32/73, 44%) were the most common abnormality (Fig-
u r e  4 ) ;  i s o l a t e d  l o s s  o f  c h r o m o s o m e  1 ,  h o w e v e r ,  w a s
observed in only 8/73 (11%) of ROs.
ChRCCs consistently showed multiple chromosomal
abnormalities, and 6/20 (30%) of cases were abnormal in
all chromosomes examined (Table 2, Figure 3). The one
case with a completely normal FISH analysis was a case of
eosinophilic chromophobe renal cell carcinoma with a
Fuhrman nuclear grade 2 and a strong cytoplasmic posi-
tivity for Hale's colloidal iron. None of our negative con-
trol sections from the adjacent non-neoplastic renal
tissue showed any losses or gains exceeding the 30 and
20% threshold, respectively.
Discussion
Renal oncocytomas are relatively uncommon neoplasms
accounting for 3-7% of primary renal epithelial neo-
plasms [1-3]. The majority of RO has distinctive cyto-
architectural features that permit accurate diagnosis;
however, the occasional differential diagnostic challenge
between RO and ChRCC has been repeatedly acknowl-
edged in the literature [2,3,18,19]. Both renal oncocytoma
and chromophobe renal cell carcinoma originate form
the collecting duct intercalated cells and can therefore
share similar histomorphologic, immunophenotypical
and ultrastructural characteristics [2-5], as well as gene
expression profiles [6,7,20]. Renal oncocytomas can con-
tain foci of atypical cells and show vascular space inva-
sion or extracapsular extension not adversely affecting
the overall excellent prognosis of this neoplasm [2,3]; the
metastatic potential of RO remains controversial [21].
Although ChRCC was found to have low metastatic
potential and its prognosis and long term survival is con-
sidered to be excellent [22], ChRCC was also found to
have a potential to recur, metastasize and undergo sarco-
matoid transformation [8,9]. The difficulty to distinguish
the two neoplasms has been demonstrated by the broad
array of ancillary studies employed so far routinely in the
differential diagnosis such as electron microscopy, DNA
flow cytometry, immunohistochemistry, cytogenetics,
and FISH. A small proportion of renal epithelial neo-
plasms with eosinophilic cytoplasm cannot be defini-
tively classified based on histology alone [19].
Figure 1 A. Characteristic gross appearance of renal oncocytoma 
- well circumscribed, mahogany brown tumor with a central scar. 
Histology: B. Typical oncocytoma composed of nests and acini of po-
lygonal to round oncocytes with abundant densely granular eosino-
philic cytoplasm and round nuclei embedded in loose myxoid or 
hyalinized stroma surrounded by a delicate reticulin framework (classic 
organoid pattern). C. Closely packed cystically dilated tubules seen in 
the tubulocystic pattern. D. Mixed pattern. E. Solid pattern with com-
pactly arranged nests or sheets of oncocytes posed the biggest diag-
nostic challenge, especially in cases with its predominance. F. Typical 
oncocytes with abundant granular eosinophilic cytoplasm and round 
nuclei with smooth contours and small nucleoli.
Figure 2 Classic ChRCC composed of solid sheets, nests, acini or 
broad trabeculae of large polygonal cells with distinct cell bor-
ders and abundant, reticular, variably eosinophilic cytoplasm 
and irregular nuclei with wrinkled nuclear membrane and peri-
nuclear halos.Dvorakova et al. Diagnostic Pathology 2010, 5:32
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Based on published cytogenetic studies, ROs are genet-
ically heterogeneous tumors. Fűzesi et.al proposed sub-
classification into 3 groups: the first one defined by
translocation between 11q13 and other chromosomes,
the second with a loss of 1/1p followed by loss of chromo-
some Y or 14, and the third with non-recurrent or no
detectable aberrations [10]. Prior FISH studies have
detected a varying incidence of partial or total loss of
chromosome 1 in RO ranging from 10 - 59% [11-13],
whereas loss of other autosomes was not detected. In
contrast, ChRCCs were consistently found to have multi-
ple recurrent chromosomal abnormalities, such as losses
Figure 3 Spectrum of chromosomal abnormalities in renal oncocytomas observed in our study using fluorescent in-situ hybridization pan-
el. In addition to isolated loss of chromosome 1, a wide variety of combined losses was detected. The previously described chromosomal profile (no 
abnormalities or isolated loss of chromosome 1) could possibly distinguish renal oncocytoma from ChRCC; however, these were seen in only 30% of 
renal oncocytomas in our study. In contrary, one of the ChRCCs with typical morphology and positivity for Hale's colloidal iron showed no chromo-
somal abnormalities.
Loss of 1, 2, 17
10%








Others (less than 
3%)
14%
Loss of 1, 2, 7
3%
Gain of 7, 17
3%








Figure 4 Most common chromosomal abnormalities in renal oncocytoma observed in the current study using fluorescent in-situ hybrid-
ization analysis: A - Loss of chromosome 1, B - Loss of chromosome 17.Dvorakova et al. Diagnostic Pathology 2010, 5:32
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of chromosomes 1, 2, 6, 10, 13, 17 and 21 by FISH, con-
ventional cytogenetics and comparative genomic hybrid-
ization [12,15,16,18,22]. No significant difference in
chromosomal abnormalities was found between the clas-
sic and eosinophilic variant of ChRCC [12]. Since both
RO and ChRCC can show loss of chromosomes 1 and Y, it
was hypothesized that a subset of ROs may progress to
ChRCC with subsequent loss of chromosomes 2, 6, 10,
13, 17 and 21 [23].
Based on the above data, we have employed an abbrevi-
ated FISH panel for chromosomes 1, 2, 7 and 17 to guide
us in the differential diagnosis of renal epithelial neo-
plasms with eosinophilic cytoplasm. Whereas an isolated
loss of chromosome 1 would favor the diagnosis of RO,
multiple losses of chromosomes 1, 2 and 17 were
expected in ChRCC cases. Although abnormalities
involving chromosome 7 are not specific and have been
reported in other types of malignancies, we included this
chromosome since its trisomy (together with trisomy 17)
was observed in papillary renal cell carcinoma [24,25]
that can rarely contribute to the pool of unclassifiable
cases of renal epithelial neoplasms with eosinophilic
cytoplasm.
In our current study, the incidence of chromosomal
abnormalities in ROs (60/73 cases, 82%) was significantly
higher than in the previous reports [10,12,18]. Brunelli et
al. [12] analyzed 10 RO by FISH using centromeric probes
for chromosomes 1, 2, 6, 10 and 17; only one case showed
loss of signal for chromosome 1, and no other aberrations
were detected. The criteria for chromosomal losses were
similar (22 - 30% of cells with one signal vs. 30% in the
current study); however, the number of nuclei examined
in our study was lower (60 vs. 100 - 200), but sufficient for
overall assessment. Only one similar case of an inciden-
tally discovered RO with multiple chromosomal losses
involving chromosomes 1, 2, 3, 6, 8, 9, 15, 17, 21 and 22 in
a 55-year-old male was identified in the literature [26].
The second most common genetic alteration in our sub-
set of RO was the loss of signal for chromosome 17 (32/
73, 44%); a common finding reported in ChRCCs and also
observed in the control ChRCC subset in our study.
Recently, a tumor suppressor gene associated with Birt-
Hogg-Dubé syndrome was mapped to the pericentro-
meric region of 17p chromosome [27-30]. Birt-Hogg-
Dubé syndrome is a rare genodermatosis characterized
by the development of dermatologic lesions (fibrofollicu-
lomas, trichodiscomas, acrochordons), lung cysts with
spontaneous pneumothorax, colonic polyps and also
renal tumors, mainly hybrid oncocytic neoplasms with
both ChRCC and RO morphology, ChRCCs, clear cell
carcinomas, oncocytomas and papillary renal cell carci-
nomas [31].
A total of 3/73 RO cases showed loss of chromosome 1
and gain of chromosome 7 and/or 17; morphologically, 2
cases displayed characteristic alternating nested and
organoid growth patterns; the third case had predomi-
nantly tubulocystic arrangement of typical oncocytes. All
three were initially diagnosed as RO without any ancillary
studies. Gains of chromosome 7 and/or 17 without any
accompanying chromosomal loss was observed in 4/73
cases; histologic review confirmed the initial diagnosis of
RO in all four cases; however, only some of the original
histologic sections were available for review in 3 cases
precluding a definitive diagnosis. RO cases with extracap-
sular or vascular space invasion usually showed multiple
chromosomal losses or gains; however, one of the cases
with perirenal soft tissue extension was normal by FISH.
Long term follow-up of patients included in our study
confirmed the excellent prognosis of RO as none of the
patients died of disease, developed metastases or local
recurrence. No association was found between overall
patient survival and the extent of chromosomal abnor-
malities detected by FISH.
The incidence of chromosomal abnormalities in
ChRCC was in agreement with previous studies
[12,15,16]; 19/20 (95%) cases showed multiple losses
involving chromosomes 1, 2 and 17 in different combina-
tions; in addition, loss of chromosome 7 was observed in
6/20(30%) cases and 6/20 (30%) cases showed loss of sig-
nals for all chromosomes examined (Figure 2). A total of
3/20 (all classic ChRCCs positive for colloidal iron) had
chromosomal losses associated with gains of chromo-
some 7 and/or 17. Only one case did not show any gains
or losses; review of the slides revealed an eosinophilic
variant of ChRCC with a strong cytoplasmic positivity for
colloidal iron (Figure 3). Rare cases of ChRCCs with no
chromosomal abnormality have been reported [12,16].
One patient in the control ChRCC group developed local
recurrence 25 months after partial nephrectomy; the
reminder of the patients was disease free or died of other
causes.
Our FISH study of ROs, which is largest to date, was
based on a series of well-defined oncocytomas diagnosed
according to the current morphologic WHO classifica-
t i o n  c r i t e r i a  [ 1 ] .  O u r  r e s u l t s  s h o w  t h a t  c h r o m o s o m a l
abnormalities in ROs are common and include frequent
losses of chromosomes 1 and 17, yet another feature that
overlaps with ChRCCs. FISH was not found to be a useful
diagnostic modality in the differential diagnosis of RO
and ChRCC and did not alter the initial primarily mor-
phology-based diagnosis of renal oncocytoma in any of
the 73 cases. Our results suggest that RO and ChRCC are
genetically related tumors and support the hypothesis
that they might rather represent a spectrum of neoplasia
than two distinct neoplasms. This finding is further sup-
ported by the concurrent RO and ChRCC as well as their
hybrid form in patients with Birt-Hogg-Dubé syndrome.
The significance of specific combinations of chromo-Dvorakova et al. Diagnostic Pathology 2010, 5:32
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somal abnormalities as well as the impact on prognosis,
propensity to metastasize, recur and undergo sarcoma-
toid transformation remains to be further investigated.
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